Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Icahn School of Medicine at Mount Sinai
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Icahn School of Medicine at Mount Sinai
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 12, 2020
Lead Product(s) : Aminolevulinic Acid HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable